ADVANCED DRUG DELIVERY REVIEWS

期刊基本信息

  • 期刊名称:ADVANCED DRUG DELIVERY REVIEWS
  • 期刊级别: Science Citation Index Expanded (SCIE) Scopus (CiteScore)
  • 期刊ISSN:0169-409X
  • 期刊EISSN:1872-8294
  • 简称:ADV DRUG DELIVER REV
  • 影响因子:17.6
  • 实时影响因子:截止2025年5月19日:17.298
  • 五年影响因子:19.2
  • JCI期刊引文指标:2.31
  • h-index:278
  • 2024-2025自引率:2.80%
  • 期刊官方网站:期刊官方网站
  • 期刊投稿网址:https://www.editorialmanager.com/ADDR
  • 是否OA开放访问:No
  • 出版商:Elsevier
  • 出版年份:1987

ADVANCED DRUG DELIVERY REVIEWS

Science Citation Index Expanded (SCIE)Scopus (CiteScore)

期刊介绍

The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery.

In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.

Articles review the current status of a specific topic, giving equal emphasis to the identification of major conceptual and technological challenges to successful drug and gene delivery, to an evaluation of triumphs as well as shortcomings in current conceptual and technical approaches, and to a discussion of their possible solution.

期刊语言要求

Language
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service.

投稿要求

  • 通讯方式:ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE
  • 涉及的研究方向:医学-药学
  • 出版国家或地区:NETHERLANDS
  • 出版语言:English
  • 年文章数:111
  • PubMed Central (PMC)链接:http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0169-409X%5BISSN%5D
  • 平均录用比例:多是约稿

CITESCORE

CiteScoreSJRSNIPCiteScore排名
36.003.7212.485
学科分区排名百分位
大类:Pharmacology, Toxicology and Pharmaceutics
小类:Pharmaceutical Science
Q11 / 185
99%

WOS期刊JCR分区

WOS分区等级:1区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ14/352
99%
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:PHARMACOLOGY & PHARMACYSCIEQ18/353
97.88%

期刊分区表预警名单

2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中

中科院2025年3月升级版

点击查看中国科学院期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区1区2区
PHARMACOLOGY & PHARMACY
药学
3区3区1区

中科院2023年12月旧的升级版

大类学科小类学科Top期刊综述期刊
医学 2区1区2区
PHARMACOLOGY & PHARMACY
药学
3区3区1区

联系我们

QQ:1211130760

微信:iqkan555

微信扫码加好友 微信扫码加好友
QQ扫码加好友 QQ扫码加好友